Rapidly growing mycobacteria: Emerging pathogens in cosmetic procedures of the skin

Clinical Infectious Diseases

Volumn 49, Issue 9, 2009, Pages 1365-1368

  Van Dissel, Jaap T ^a   Kuijper, Ed J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOXITIN; CLARITHROMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ETHAMBUTOL; GAMMA INTERFERON; IMIPENEM; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; INTERNAL TRANSCRIBED SPACER; ISONIAZID; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TIGECYCLINE; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIAL VIRULENCE; DRUG EFFICACY; EPIDEMIC; ESTHETIC SURGERY; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MYCOBACTERIOSIS; MYCOBACTERIUM; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM CHELONEI; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM IMMUNOGENUM; NONHUMAN; NOTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN INFECTION;

ADULT; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; COSMETIC TECHNIQUES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM CHELONAE; MYCOBACTERIUM INFECTIONS; SKIN DISEASES, BACTERIAL; SUBCUTANEOUS FAT; YOUNG ADULT;

EID: 72849137547     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/606051     Document Type: Note

References (35)

1. Grice EA, Kong HH, Conlan S. Topographical and temporal diversity of the human skin microbiome. Science 2009; 324:1190-1192
2. Proksch E, Brandner JM, Jensen JM. The skin: an indispensible barrier. Exp Dermatol 2008; 17:1063-1072
3. Regnier S, Cambau E, Meningaud J-P, et al. Clinical management of rapidly growing mycobacterial cutaneous infections in patients after mesotherapy. Clin Infect Dis 2009; 49: 1358-1364 (in this issue).
4. Munayco CV, Grijalva CG, Culqui DR, et al. Outbreak of persistent cutaneous abscesses due to Mycobacterium chelonae after mesotherapy sessions, Lima, Peru. Rev Saude Publica 2008; 42:146-149
5. . Sañudo A, Vallejo F, Sierra M, et al. Nontuberculous mycobacteria infection after mesotherapy: preliminary report of 15 cases. Int J Dermatol 2007; 46:649-653 (Pubitemid 46909413) (Pubitemid 46909413)
6. Del-Castillo M, Palmero D, Lopez B, et al. Mesotherapy-associated outbreak caused by Mycobacterium immunogenum. Emerg Infect Dis 2009; 15:357-359
7. Garcia-Navarro X, Barnadas MA, Dalmau J, et al. Mycobacterium abscessus infection secondary to mesotherapy. Clin Exp Dermatol 2008; 33:658-659
8. Difonzo EM, Campanile GL, Vanzi L, Lotti L. Mesotherapy and cutaneous Mycobacterium fortuitum infection. Int J Dermatol 2009; 48: 645-647
9. Hay RJ. Mycobacterium chelonae: a growing problem in soft tissue infection. Curr Opin Infect Dis 2009; 22:99-101.
10. Brown-Elliott BA, Wallace RJ. Mycobacterium: clinical and laboratory characteristics of rapidly growing mycobacteria. In: Manual of clinical microbiology. 9th ed. Washington, DC: ASM Press, 2007.
11. Escalonilla P, Estaban J, Soriano ML, et al. Cutaneous manifestations of infection by nontuberculous mycobacteria. Clin Exp Dermatol 1998; 23:214-221 (Pubitemid 28566269) (Pubitemid 28566269)
12. Liao CH, Lai CC, Ding LW, et al. Skin and soft tissue infection caused by non-tuberculous mycobacteria. Int J Tuberc Lung Dis 2007; 11:96-102. (Pubitemid 46101853)
13. Mycobacterium chelonae infections associated with face lifts: New Jersey, 2002-2003. MMWR Morb Mortal Wkly Rep 2004; 53: 192-194
14. Preda VA, Maley M, Sullivan JR. Mycobacterium chelonae infection in a tattoo site. Med J Aust 2009; 190:278-279
15. Uslan DZ, Kowalski TJ, Wengenack NL, et al. Skin and soft tissue infections due to rapidly growing mycobacteria: comparison of clinical features, treatment, and susceptibility. Arch Dermatol 2006; 142:1287.
16. Dodiuk-Gad R, Dyachenko P, Ziv M, et al. Nontuberculous mycobacterial infections of the skin: a retrospective study of 25 cases. J Am Acad Dermatol 2007; 57:413-420 (Pubitemid 47239136) (Pubitemid 47239136)
17. Adhikesavan LG, Harrington TM. Local and disseminated infections caused by Mycobacterium marinum: an unusual cause of subcutaneous nodules. J Clin Rheumatol 2008; 14:156-160
18. Winthrop KL, Abrams M, Yakrus M, et al. An outbreak of mycobacterial furunculosis associated with footbaths at a nail salon. N Engl J Med 2002; 346:1366-1371 (Pubitemid 34754609) (Pubitemid 34754609)
19. Bartralot R, Garcia-Patos V, Sitjas D, et al. Clinical patterns of cutaneous nontuberculous mycobacterial infections. Br J Dermatol 2005; 152:727-734 (Pubitemid 40571306) (Pubitemid 40571306)
20. Haverkamp MH, van Dissel JT, Holland SM. Human host genetic factors in nontuberculous mycobacterial infection: lessons fromsingle gene disorders affecting innate and adaptive immunity and lessons from molecular defects in interferon gamma-dependent signaling. Microbes Infect 2006; 8:1157-1166
21. Dorman SE, Picard C, Lammas D, et al. Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. Lancet 2004; 364:2113-2121 (Pubitemid 39626807) (Pubitemid 39626807)
22. Russo C, Tortoli E, Menichella D. Evaluation of the new GenoType Mycobacterium assay for identification of mycobacterial species. J Clin Microbiol 2006; 44:334-339
23. Tortoli E, Mariottini A, Mazzarelli G. Evaluation of INNO-Lipa mycobacteria v2: improved reverse hybridization multiple DNA probe assay for mycobacterial identification. J Clin Microbiol 2003; 41:4418-4420 (Pubitemid 37099719) (Pubitemid 37099719)
24. Bruijnesteijn Van Coppenraet ES, Lindeboom JA, Prins JM, et al. Real-time PCR assay using fine-needle aspirates and tissue biopsy specimens for rapid diagnosis of mycobacterial lymphadenitis in children. J Clin Microbiol 2004; 42:2644-2650
25. Lindeboom JA, Kuijper EJ, Bruijnesteijn van Coppenraet ES, Lindeboom R, Prins JM. Surgical excision versus antibiotic treatment for nontuberculous mycobacterial cervicofacial lymphadenitis in children: a multicenter, randomized, controlled trial. Clin Infect Dis 2007; 44:1057-1064 (Pubitemid 46580272) (Pubitemid 46580272)
26. Wallace RJ Jr, Swenson JM, Silcox VA, Bullen MG. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. J Infect Dis 1985; 152:500-514
27. Heifets LB. Antimycobacterial drugs. Semin Respir Infect 1994; 9:84-103.
28. Wallace RJ Jr, Tanner D, Brennan PJ, Brown BA. Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae. Ann Intern Med 1993; 119:482-486
29. Tebas P, Sultan F,Wallace RJ Jr, FraserV. Rapid development of resistance to clarithromycin following monotherapy for disseminated Mycobacterium chelonae infection in a heart transplant patient. Clin Infect Dis 1995; 20:443-444
30. Brown-Elliott BA,Wallace RJ, Blinkhorn R, et al. Successful treatment of disseminated Mycobacterium chelonae infection with linezolid. Clin Infect Dis 2001; 33:1433-1434
31. Wallace RJ Jr, Brown-Elliott BA, Ward SC, et al. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 2001; 45:764-767 (Pubitemid 32182022) (Pubitemid 32182022)
32. Wallace RJ, Brown-Elliott BA, Crist CJ, et al. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of non-tuberculous mycobacteria. Antimicrob Agents Chemother 2002; 46:3164-3167
33. Dessy LA, Mazzocchi M, Fioramonti P, Scuderi N. Conservative management of local Mycobacterium chelonae infection after combined liposuction and lipofilling. Aesthetic Plast Surg 2006; 30:717-722
34. Zeharia A, Eidlitz-Markus T, Haimi-Cohen Y, et al. Management of nontuberculous mycobacteria-induced cervical lymphadenitis with observation alone. Pediatr Infect Dis J 2008; 27:920-922
35. Polesky A, Grove W, Bhatia G. Peripheral tuberculous lymphadenitis: epidemiology, diagnosis, treatment, and outcome. Medicine 2005; 84:350-362 (Pubitemid 41668934) (Pubitemid 41668934)